
<http://bio2rdf.org/drugbank:DB00020> a <http://schema.org/Drug> ;
	<http://schema.org/name> "Sargramostim" ;
	<http://schema.org/description> "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein." ;
	<http://schema.org/drugClass> "Immunosuppressive Agents" ;
	<http://schema.org/url> "http://bio2rdf.org/drugbank:DB00020" ;
	<http://schema.org/administrationRoute> "intravenous; subcutaneous" ;
	<http://schema.org/availableStrength> <http://bio2rdf.org/drugbank_resource:160e9b045b741d536d7268b25c5c0a17> , <http://bio2rdf.org/drugbank_resource:7e1dc2152a5d0a4aecccec7ca96179dc> ;
	<http://schema.org/clinicalPharmacology> "Sargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy an recovering from acut myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections." ;
	<http://schema.org/cost> <http://bio2rdf.org/drugbank_resource:56ca4f2a80724a127043df6e4fa0ded0> , <http://bio2rdf.org/drugbank_resource:73124cd4366d24e39216120daaa16ff0> ;
	<http://schema.org/dosageForm> "Injection, powder, for solution" , "Liquid" ;
	<http://schema.org/interactingDrug> "DDI between Sargramostim and Bleomycin - Sargramostim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased." , "DDI between Sargramostim and Cyclophosphamide - May enhance the adverse/toxic effect of Sargramostim. Specifically, the risk of pulmonary toxicity may be enhanced." ;
	<http://schema.org/legalStatus> "Approved" , "Investigational" ;
	<http://schema.org/mechanismOfAction> "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils" ;
	<http://schema.org/nonProprietaryName> "GM-CSF" ;
	<http://schema.org/proprietaryName> "Leucomax" ;
	<http://schema.org/identifier> "drugbank:DB00020" ;
	<http://schema.org/sameAs> <http://www.drugbank.ca/drugs/DB00020> , <http://www.rxlist.com/cgi/generic/sargramostim.htm> , <http://www.drugs.com/cdi/sargramostim.html> .

<http://bio2rdf.org/drugbank_resource:160e9b045b741d536d7268b25c5c0a17> a <http://schema.org/DrugStrength> ;
	<http://schema.org/description> "250 ug/mL Injection, powder, for solution form with intravenous; subcutaneous route" .

<http://bio2rdf.org/drugbank_resource:56ca4f2a80724a127043df6e4fa0ded0> a <http://schema.org/DrugCost> ;
	<http://schema.org/costPerUnit> "0.41999998688697814941" ;
	<http://schema.org/costCurrency> "USD" ;
	<http://schema.org/drugUnit> "Bio-immunex capsule" .

<http://bio2rdf.org/drugbank_resource:73124cd4366d24e39216120daaa16ff0> a <http://schema.org/DrugCost> ;
	<http://schema.org/costPerUnit> "204.7899932861328125" ;
	<http://schema.org/costCurrency> "USD" ;
	<http://schema.org/drugUnit> "Leukine 250 mcg vial" .

<http://bio2rdf.org/drugbank_resource:7e1dc2152a5d0a4aecccec7ca96179dc> a <http://schema.org/DrugStrength> ;
	<http://schema.org/description> "500 ug/mL Liquid form with intravenous; subcutaneous route" .
